tetano
Editor, Senior Moderator
Virology
. 2022 Mar 6;569:56-63.
doi: 10.1016/j.virol.2022.03.001. Online ahead of print.
Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
Taotao Mi[SUP] 1 [/SUP], Tiantian Wang[SUP] 2 [/SUP], Huifang Xu[SUP] 2 [/SUP], Peng Sun[SUP] 2 [/SUP], Xuchen Hou[SUP] 2 [/SUP], Xinwei Zhang[SUP] 3 [/SUP], Qian Ke[SUP] 4 [/SUP], Jiawen Liu[SUP] 2 [/SUP], Shengwei Hu[SUP] 5 [/SUP], Jun Wu[SUP] 6 [/SUP], Bo Liu[SUP] 7 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) kappa (B.1.617.1) variant represented the main variant of concern (VOC) for the epidemic in India in May 2021. We have previously established a technology platform for rapidly preparing SARS-CoV-2 receptor-binding domain (RBD) candidate vaccines based on glycoengineered Pichia pastoris. Our previous study revealed that the wild-type RBD (WT-RBD) formulated with aluminum hydroxide and CpG 2006 adjuvant effectively induces neutralizing antibodies in BALB/c mice. In the present study, a glycoengineered P. pastoris expression system was used to prepare recombinant kappa-RBD candidate vaccine. Kappa-RBD formulated with CpG and alum induced BALB/c mice to produce a potent antigen-specific antibody response and neutralizing antibody titers against pseudoviruses of SARS-CoV-2 kappa, delta, lambda, beta, and omicron variants and WT. Therefore, the recombinant kappa-RBD vaccine has sufficient potency to be a promising COVID-19 vaccine candidate.
Keywords: Receptor-binding domain (RBD); SARS-CoV-2 kappa; Vaccine; Yeast.
. 2022 Mar 6;569:56-63.
doi: 10.1016/j.virol.2022.03.001. Online ahead of print.
Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
Taotao Mi[SUP] 1 [/SUP], Tiantian Wang[SUP] 2 [/SUP], Huifang Xu[SUP] 2 [/SUP], Peng Sun[SUP] 2 [/SUP], Xuchen Hou[SUP] 2 [/SUP], Xinwei Zhang[SUP] 3 [/SUP], Qian Ke[SUP] 4 [/SUP], Jiawen Liu[SUP] 2 [/SUP], Shengwei Hu[SUP] 5 [/SUP], Jun Wu[SUP] 6 [/SUP], Bo Liu[SUP] 7 [/SUP]
Affiliations
- PMID: 35276485
- PMCID: PMC8898337
- DOI: 10.1016/j.virol.2022.03.001
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) kappa (B.1.617.1) variant represented the main variant of concern (VOC) for the epidemic in India in May 2021. We have previously established a technology platform for rapidly preparing SARS-CoV-2 receptor-binding domain (RBD) candidate vaccines based on glycoengineered Pichia pastoris. Our previous study revealed that the wild-type RBD (WT-RBD) formulated with aluminum hydroxide and CpG 2006 adjuvant effectively induces neutralizing antibodies in BALB/c mice. In the present study, a glycoengineered P. pastoris expression system was used to prepare recombinant kappa-RBD candidate vaccine. Kappa-RBD formulated with CpG and alum induced BALB/c mice to produce a potent antigen-specific antibody response and neutralizing antibody titers against pseudoviruses of SARS-CoV-2 kappa, delta, lambda, beta, and omicron variants and WT. Therefore, the recombinant kappa-RBD vaccine has sufficient potency to be a promising COVID-19 vaccine candidate.
Keywords: Receptor-binding domain (RBD); SARS-CoV-2 kappa; Vaccine; Yeast.